{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:13:45Z","timestamp":1777493625658,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10067-022-06166-3","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T01:02:25Z","timestamp":1649638945000},"page":"2803-2808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-\u03b3, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis\/polymyositis in a Japanese community hospital"],"prefix":"10.1007","volume":"41","author":[{"given":"Takeshi","family":"Suga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-8616","authenticated-orcid":false,"given":"Hiroshi","family":"Oiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"6166_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/BOR.0b013e3282f01a8c","volume":"19","author":"T Mimori","year":"2007","unstructured":"Mimori T, Imura Y, Nakashima R, Yoshifuji H (2007) Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 19:523\u2013529. https:\/\/doi.org\/10.1097\/BOR.0b013e3282f01a8c","journal-title":"Curr Opin Rheumatol"},{"key":"6166_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/annrheumdis-2017-211402","volume":"77","author":"GC Dobloug","year":"2018","unstructured":"Dobloug GC, Svensson J, Lundberg IE, Holmqvist M (2018) Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 77:40\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211402","journal-title":"Ann Rheum Dis"},{"key":"6166_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","volume":"134","author":"R Buchbinder","year":"2001","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087\u20131095. https:\/\/doi.org\/10.7326\/0003-4819-134-12-200106190-00008","journal-title":"Ann Intern Med"},{"key":"6166_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","volume":"19","author":"H Yang","year":"2017","unstructured":"Yang H, Peng Q, Yin L et al (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19:259. https:\/\/doi.org\/10.1186\/s13075-017-1469-8","journal-title":"Arthritis Res Ther"},{"key":"6166_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/rheumatology\/key357","volume":"58","author":"A Oldroyd","year":"2019","unstructured":"Oldroyd A, Sergeant JC, New P et al (2019) The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 58:650\u2013655. https:\/\/doi.org\/10.1093\/rheumatology\/key357","journal-title":"Rheumatology (Oxford)"},{"key":"6166_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/art.33403","volume":"64","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, Hamaguchi Y, Kaji K et al (2012) Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513\u2013522. https:\/\/doi.org\/10.1002\/art.33403","journal-title":"Arthritis Rheum"},{"key":"6166_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/1756-185X.14046","volume":"24","author":"Y Li","year":"2021","unstructured":"Li Y, Jia X, Sun X et al (2021) Risk factors for cancer-associated myositis: a large-scale multicenter cohort study. Int J Rheum Dis 24:268\u2013273. https:\/\/doi.org\/10.1111\/1756-185X.14046","journal-title":"Int J Rheum Dis"},{"key":"6166_CR8","unstructured":"Ogawa-Momohara M, Muro Y, Mitsuma T, et al (2018). Strong correlation between cancer progression and anti-transcription intermediary factor 1\u03b3 antibodies in dermatomyositis patients. Clin Exp Rheumatol 36:990\u2013995.\u00a0https:\/\/www.clinexprheumatol.org\/abstract.asp?a=12403. Accessed 10 Apr 2022"},{"key":"6166_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","volume":"71","author":"Y Ichimura","year":"2012","unstructured":"Ichimura Y, Matsushita T, Hamaguchi Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:710\u2013713. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200697","journal-title":"Ann Rheum Dis"},{"key":"6166_CR10","doi-asserted-by":"publisher","unstructured":"Ichimura Y, Konishi R, Shobo M et al (Online ahead of print). Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab518","DOI":"10.1093\/rheumatology\/keab518"},{"key":"6166_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. I N Engl J Med 292:344\u2013347. https:\/\/doi.org\/10.1056\/NEJM197502132920706","journal-title":"I N Engl J Med"},{"key":"6166_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. II N Engl J Med 292:403\u2013407. https:\/\/doi.org\/10.1056\/NEJM197502202920807","journal-title":"II N Engl J Med"},{"key":"6166_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","volume":"54","author":"P Gerami","year":"2006","unstructured":"Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54:597\u2013613. https:\/\/doi.org\/10.1016\/j.jaad.2005.10.041","journal-title":"J Am Acad Dermatol"},{"key":"6166_CR14","doi-asserted-by":"publisher","first-page":"e85062","DOI":"10.1371\/journal.pone.0085062","volume":"9","author":"R Nakashima","year":"2014","unstructured":"Nakashima R, Imura Y, Hosono Y et al (2014) The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS ONE 9:e85062. https:\/\/doi.org\/10.1371\/journal.pone.0085062","journal-title":"PLoS ONE"},{"key":"6166_CR15","doi-asserted-by":"publisher","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285.10.1371\/journal.pone.0154285","volume":"11","author":"S Sato","year":"2016","unstructured":"Sato S, Murakami A, Kuwajima A et al (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11:e0154285. https:\/\/doi.org\/10.1371\/journal.pone.0154285.10.1371\/journal.pone.0154285","journal-title":"PLoS One"},{"key":"6166_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","volume":"84","author":"M Fujimoto","year":"2016","unstructured":"Fujimoto M, Murakami A, Kurei S et al (2016) Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. J Dermatol Sci 84:272\u2013281. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.09.013","journal-title":"J Dermatol Sci"},{"key":"6166_CR17","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1007\/s10067-020-04973-0","volume":"39","author":"Y Hamaguchi","year":"2020","unstructured":"Hamaguchi Y, Kuwana M, Takehara K (2020) Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies. Clin Rheumatol 39:3489\u20133497. https:\/\/doi.org\/10.1007\/s10067-020-04973-0","journal-title":"Clin Rheumatol"},{"key":"6166_CR18","doi-asserted-by":"publisher","unstructured":"Zidane M, Dressler C, Nast A, Egeberg A (2020). Incidences of different cancer types in dermatomyositis, polymyositis and dermatopolymyositis: results of a registry analysis. Br J Dermatol 183:186\u2013188. https:\/\/doi.org\/10.1111\/bjd.18948","DOI":"10.1111\/bjd.18948"},{"key":"6166_CR19","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","volume":"60","author":"AGS Oldroyd","year":"2021","unstructured":"Oldroyd AGS, Allard AB, Callen JP et al (2021) A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford) 60:2615\u20132628. https:\/\/doi.org\/10.1093\/rheumatology\/keab166","journal-title":"Rheumatology (Oxford)"},{"key":"6166_CR20","doi-asserted-by":"publisher","first-page":"e0154746","DOI":"10.1371\/journal.pone.0154746","volume":"11","author":"N Mugii","year":"2016","unstructured":"Mugii N, Hasegawa M, Matsushita T et al (2016) Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS ONE 11:e0154746. https:\/\/doi.org\/10.1371\/journal.pone.0154746","journal-title":"PLoS ONE"},{"key":"6166_CR21","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF (2017) Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1909\u20131914. https:\/\/doi.org\/10.1002\/acr.23210","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6166_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/acr.23188","volume":"69","author":"J Albayda","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W et al (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1771\u20131776. https:\/\/doi.org\/10.1002\/acr.23188","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6166_CR23","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","volume":"3","author":"M Kadoya","year":"2016","unstructured":"Kadoya M, Hida A, Hashimoto Maeda M et al (2016) Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm 3:e290. https:\/\/doi.org\/10.1212\/NXI.0000000000000290","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06166-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T07:06:11Z","timestamp":1663139171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06166-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6166"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06166-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"20 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"This study complied with the Declaration of Helsinki, and the institutional review board of Hiroshima City Hiroshima Citizens Hospital approved this study (approval no. 2021\u2013101). The need to obtain informed consent from patients was waived in accordance with the regulations for retrospective cohort studies. Information for patients regarding this study was provided on the hospital website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}